An eHealth decision‐support tool to prioritize referral practices for genetic evaluation of patients with Wilms tumor
暂无分享,去创建一个
R. Weksberg | W. Foulkes | D. Malkin | L. Reichman | Catherine Goudie | D. Stephens | G. Somers | A. Villani | R. Grant | N. Cullinan | Kalene van Engelen | Stéphanie Mourad
[1] S. Seal,et al. Identification of new Wilms tumour predisposition genes: an exome sequencing study , 2019, The Lancet. Child & adolescent health.
[2] M. Gessler,et al. TRIM28 haploinsufficiency predisposes to Wilms tumor , 2019, International journal of cancer.
[3] R. Hennekam,et al. Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith–Wiedemann syndrome: an international consensus statement , 2018, Nature Reviews Endocrinology.
[4] W. Foulkes,et al. The McGill Interactive Pediatric OncoGenetic Guidelines: An approach to identifying pediatric oncology patients most likely to benefit from a genetic evaluation , 2017, Pediatric blood & cancer.
[5] J. Mulliken,et al. Sonographic screening for Wilms tumor in children with CLOVES syndrome , 2017, Pediatric blood & cancer.
[6] C. Shaw,et al. Mutations in the transcriptional repressor REST predispose to Wilms tumor , 2015, Nature Genetics.
[7] J. Soulier,et al. Fanconi anemia and solid malignancies in childhood: A national retrospective study , 2015, Pediatric blood & cancer.
[8] S. Seal,et al. Germline mutations in the PAF1 complex gene CTR9 predispose to Wilms tumour , 2014, Nature Communications.
[9] H. Brisse,et al. Malformations, genetic abnormalities, and wilms tumor , 2014, Pediatric blood & cancer.
[10] R. Pieters,et al. Frequency of WT1 and 11p15 constitutional aberrations and phenotypic correlation in childhood Wilms tumour patients. , 2012, European journal of cancer.
[11] J. Opitz,et al. Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibility , 2012, Nature Genetics.
[12] W. Foulkes,et al. Extending the phenotypes associated with DICER1 mutations , 2011, Human mutation.
[13] N. Breslow,et al. Risk factors for end stage renal disease in non-WT1-syndromic Wilms tumor. , 2011, The Journal of urology.
[14] James R. Anderson,et al. The Management of Synchronous Bilateral Wilms Tumor: A Report from the National Wilms Tumor Study Group , 2011, Annals of surgery.
[15] E. Denamur,et al. Management of Wilms tumors in Drash and Frasier syndromes , 2009, Pediatric blood & cancer.
[16] N. Breslow,et al. Age distributions, birth weights, nephrogenic rests, and heterogeneity in the pathogenesis of Wilms tumor , 2006, Pediatric blood & cancer.
[17] N. Rahman,et al. Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour , 2006, Journal of Medical Genetics.
[18] Bernard V Fischbach,et al. WAGR Syndrome: A Clinical Review of 54 Cases , 2005, Pediatrics.
[19] N. Rahman,et al. Frequency and heritability of WT1 mutations in nonsyndromic Wilms' tumor patients: a UK Children's Cancer Study Group Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] V. Huff,et al. Twenty‐four new cases of WT1 germline mutations and review of the literature: Genotype/phenotype correlations for Wilms tumor development , 2004, American journal of medical genetics. Part A.
[21] A. Kelsey,et al. The treatment of Wilms' tumour: results of the United Kingdom Children's Cancer Study Group (UKCCSG) second Wilms' tumour study , 2000, British Journal of Cancer.
[22] S. Schneider,et al. Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[23] N Breslow,et al. Epidemiology of Wilms tumor. , 1993, Medical and pediatric oncology.